Clinical Trials Logo

Prostate clinical trials

View clinical trials related to Prostate.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06192758 Recruiting - Cancer Clinical Trials

First In Human Dose Escalation Study Evaluating Safety of TheraSphere Prostate Cancer (PCa) Device

VOYAGER
Start date: April 2024
Phase: N/A
Study type: Interventional

The VOYAGER Study is an interventional, non-randomized, single-arm, dose escalation trial with the goal of determining the safety of TheraSphere PCa device in patients with clinically localized prostate cancer across US-based centers.

NCT ID: NCT04518072 Recruiting - Cancer Clinical Trials

Synthetic Metabolic and Genetic Networks for Medical Diagnosics

SynBioDiag
Start date: January 6, 2021
Phase:
Study type: Observational

This is a category 3 human study, prospective, comparative, in parallel groups. A comparative qualitative and quantitative analysis of several markers in 250 samples is proposed.

NCT ID: NCT00923221 Recruiting - Prostate Cancer Clinical Trials

Collection of Blood From Patients With Prostate Cancer

Start date: February 28, 2007
Phase:
Study type: Observational

Background: - It is not fully understood why prostate cancer in some men becomes androgen-independent (no longer responds to anti-androgen medication), but genetics likely plays an important role. - Genes contain the hereditary information that is passed down from parents to children. Although everyone has the same set of genes, individuals can have different forms of the same gene. - Differences in genes may explain, at least in part, why some people develop a more aggressive form of prostate cancer than others. Objectives: -To obtain blood samples from patients with prostate cancer to try to identify gene differences associated with progression to the androgen independent state. Eligibility: -All participants participating in NCI prostate cancer protocols. Design: - Participants with prostate cancer are evaluated in the NCI s Medical Oncology Clinic. - Blood samples are collected at the initial visit or at follow-up visits. - DNA (genetic material) and white blood cells are extracted from these samples to be used for genotyping and establishment of cell lines. - Gene variations are correlated with prostate cancer prognosis and prognostic indicators.